MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has received clearance from the U.S. Food and Drug Administration (FDA) to begin a ...

Specialist Consultant Paediatrician and Honorary Senior Fellow, Postgraduate Institute of Medicine, University of Colombo, ...

FDA unveils a priority voucher program to accelerate drug reviews for national priorities, using a team-based review model.

Aldeyra has resubmitted its new drug application for reproxalap, an investigational dry eye treatment, which contained new ...

The biotech industry faces a mix of longstanding and novel political challenges amid President Donald Trump’s second term.

Supply chains for a new generation of therapies are complex, costly, and require meticulous management to ensure patient ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Discover six kidney disease companies actively working on innovative treatments that could make a difference to patients' lives.

The US Food and Drug Administration (FDA) has approved Ocugen’s investigational new drug (IND) amendment to initiate a Phase ...

Glaucoma is the most common cause of irreversible blindness and affects 80 million people around the world. Pete Williams, ...

Genflow Biosciences Provides Half Year Corporate Update on SIRT6 Programs, IP Progress and Strategic Partnerships LONDON, UK / ACCESS Newswire / June 17, 2025 / Genflow Biosciences Plc ...